Merck KGaA/ DE0006599905 /
2024-05-07 5:29:27 PM | Chg. - | Volume | Bid5:30:00 PM | Ask2024-05-07 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
153.48EUR | - | 72 Turnover: 11,050.20 |
-Bid Size: - | -Ask Size: - | 19.96 bill.EUR | 1.42% | 23.79 |
GlobeNewswire
10:10 PM
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
3:00 PM
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
3:00 PM
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire
2:30 PM
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Bi...
GlobeNewswire
1:00 PM
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA